

Michele Del Vecchio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1945408/publications.pdf>

Version: 2024-02-01

61
papers

5,455
citations

186265

28
h-index

123424

61
g-index

63
all docs

63
docs citations

63
times ranked

8377
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1824-1835.	27.0	1,752
2	Interleukin-12: Biological Properties and Clinical Application. <i>Clinical Cancer Research</i> , 2007, 13, 4677-4685.	7.0	517
3	Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 611-622.	10.7	428
4	Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. <i>Annals of Oncology</i> , 2016, 27, 732-738.	1.2	321
5	Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study. <i>Lancet Oncology</i> , The, 2014, 15, 436-444.	10.7	242
6	Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. <i>Journal of Translational Medicine</i> , 2014, 12, 116.	4.4	149
7	Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. <i>European Journal of Cancer</i> , 2014, 50, 121-127.	2.8	149
8	Metastatic melanoma: Chemotherapy. <i>Seminars in Oncology</i> , 2002, 29, 427-445.	2.2	146
9	Immunotherapy of Metastatic Melanoma Using Genetically Engineered GD2-Specific T cells. <i>Clinical Cancer Research</i> , 2009, 15, 5852-5860.	7.0	120
10	Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. <i>Annals of Oncology</i> , 2013, 24, 2911-2915.	1.2	119
11	Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. <i>Annals of Oncology</i> , 2015, 26, 798-803.	1.2	118
12	Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. <i>Journal of Neuro-Oncology</i> , 2014, 118, 109-116.	2.9	103
13	Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon- γ in metastatic melanoma. <i>Annals of Oncology</i> , 2006, 17, 571-577.	1.2	101
14	Boosting T Cell-Mediated Immunity to Tyrosinase by Vaccinia Virus-Transduced, CD34+-Derived Dendritic Cell Vaccination. <i>Clinical Cancer Research</i> , 2004, 10, 5381-5390.	7.0	98
15	T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both <i>In Vitro</i> and <i>In Vivo</i> . <i>Clinical Cancer Research</i> , 2014, 20, 962-971.	7.0	95
16	Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program. <i>Cancer Investigation</i> , 2014, 32, 144-149.	1.3	90
17	A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma. <i>Annals of Oncology</i> , 2015, 26, 2267-2274.	1.2	67
18	Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors. <i>Clinical Cancer Research</i> , 2010, 16, 5862-5872.	7.0	56

#	ARTICLE	IF	CITATIONS
19	Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy. <i>British Journal of Cancer</i> , 2014, 110, 1721-1726.	6.4	53
20	Treatment of cancer-related anemia with epoetin alfa: a review. <i>Cancer Treatment Reviews</i> , 2004, 30, 563-575.	7.7	52
21	Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9502-9502.	1.6	52
22	The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors. , 2019, 7, 308.		51
23	Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade. <i>Oncotarget</i> , 2016, 7, 3947-3965.	1.8	45
24	A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification. <i>Oncotarget</i> , 2015, 6, 5118-5133.	1.8	37
25	Allovetin-7 therapy in metastatic melanoma. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 839-844.	3.1	32
26	Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF V600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. <i>European Journal of Cancer</i> , 2017, 79, 176-184.	2.8	31
27	Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole. <i>Endocrine-Related Cancer</i> , 2004, 11, 771-779.	3.1	30
28	Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases?. <i>Cancer Treatment Reviews</i> , 2016, 50, 1-8.	7.7	30
29	Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e94.	2.2	29
30	Update on the treatment of neuroendocrine tumors. <i>Expert Review of Anticancer Therapy</i> , 2003, 3, 631-642.	2.4	24
31	Immunization of Patients with Malignant Melanoma with Autologous CD34+Cell-Derived Dendritic Cells Transduced Ex Vivo with a Recombinant Replication-Deficient Vaccinia Vector Encoding the Human Tyrosinase Gene: A Phase I Trial. <i>Human Gene Therapy</i> , 2003, 14, 1347-1360.	2.7	22
32	Primary Uterine Cervix Melanoma Resembling Malignant Peripheral Nerve Sheath Tumor: A Case Report. <i>International Journal of Gynecological Pathology</i> , 2008, 27, 596-600.	1.4	19
33	Levofloxacin: update and perspectives on one of the original "respiratory quinolones"™. <i>Expert Review of Anti-Infective Therapy</i> , 2003, 1, 371-387.	4.4	17
34	Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon. <i>Journal of Chemotherapy</i> , 2014, 26, 193-201.	1.5	17
35	Simultaneous transduction of B7-1 and IL-2 genes into human melanoma cells to be used as vaccine: enhancement of stimulatory activity for autologous and allogeneic lymphocytes. <i>Cancer Immunology, Immunotherapy</i> , 2001, 50, 199-211.	4.2	16
36	Renal Cancer Treatment: A Review of the Literature. <i>Tumori</i> , 2003, 89, 476-484.	1.1	16

#	ARTICLE	IF	CITATIONS
37	Doxifluridine as Palliative Treatment in Advanced Gastric and Pancreatic Cancer Patients. <i>Oncology</i> , 1996, 53, 54-57.	1.9	14
38	Cost Estimate of Immune-Related Adverse Reactions Associated with Innovative Treatments of Metastatic Melanoma. <i>Clinical Drug Investigation</i> , 2018, 38, 967-976.	2.2	14
39	Outcome Evaluation of Patients with Limited Brain Metastasis From Malignant Melanoma, Treated with Surgery, Radiation Therapy, and Targeted Therapy. <i>World Neurosurgery</i> , 2017, 105, 184-190.	1.3	13
40	An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. <i>European Journal of Cancer</i> , 2019, 107, 175-185.	2.8	13
41	Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens. <i>European Journal of Cancer</i> , 1997, 33, 687-690.	2.8	11
42	A Feasibility Study using Polychemotherapy (Cisplatin + Vindesine + Dacarbazine) plus Interferon-Alpha or Monochemotherapy with Dacarbazine plus Interferon-Alpha in Metastatic Melanoma. <i>Tumori</i> , 2001, 87, 219-222.	1.1	11
43	Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients. , 2021, 9, e001167.		11
44	Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib. <i>Oncotarget</i> , 2018, 9, 12408-12417.	1.8	11
45	Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9070-9070.	1.6	9
46	Fluoropyrimidines in the Treatment of Advanced Neoplastic Diseases: Role and Advantages of UFT. <i>Tumori</i> , 1999, 85, 6-11.	1.1	8
47	T-Cell Activation and Maturation at Tumor Site Associated With Objective Response to Ipilimumab in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2011, 29, e783-e788.	1.6	8
48	Preliminary Experience with High-Dose Cisplatin, Reduced Glutathione and Natural Interferon- α in Dacarbazine-Resistant Malignant Melanoma. <i>Tumori</i> , 1998, 84, 48-51.	1.1	7
49	Unusual Aspects of Melanoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 745-746.	1.6	7
50	A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III). <i>Cancers</i> , 2021, 13, 2466.	3.7	7
51	Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study. <i>Future Oncology</i> , 2015, 11, 1355-1362.	2.4	6
52	Combined Therapy with Dabrafenib and Trametinib in BRAF-Mutated Metastatic Melanoma in a Real-Life Setting: The INT Milan Experience. <i>Tumori</i> , 2016, 102, 501-507.	1.1	6
53	Effectiveness of dabrafenib in the treatment of patients with BRAF V600 mutated metastatic melanoma in a Named Patient Program. <i>Melanoma Research</i> , 2019, 29, 527-532.	1.2	6
54	An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9584-9584.	1.6	6

#	ARTICLE	IF	CITATIONS
55	Genetic Layout of Melanoma Lesions Is Associated with BRAF/MEK-Targeted Therapy Resistance and Transcriptional Profiles. <i>Journal of Investigative Dermatology</i> , 2022, 142, 3030-3040.e5.	0.7	6
56	Immune Suppression and Response to Ipilimumab: Assessing Risk-to-Benefit Ratio. <i>Journal of Clinical Oncology</i> , 2016, 34, 1017-1018.	1.6	5
57	Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy). <i>Targeted Oncology</i> , 2021, 16, 789-799.	3.6	5
58	Risk of disease progression (PD) following discontinuation of BRAF±MEK targeted therapies for reasons other than PD in patients (pts) with metastatic or unresectable melanoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10053-10053.	1.6	3
59	Impressive objective response in a patient with extensive metastatic melanoma including the brain. <i>Melanoma Research</i> , 2007, 17, 332-334.	1.2	1
60	Neuroendocrine tumors (NETs). <i>Clinical Therapeutics</i> , 2009, 31, 2060-2061.	2.5	1
61	An Unusually Large Pleural Mesothelioma with an Outstanding Clinical Response and Long Lasting Survival: A Case Report and Literature Review. <i>Tumori</i> , 2010, 96, 1031-1034.	1.1	1